Shots: The two companies signed a research agreement to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine’s REGENT technology, based on red blood cell extracellular vesicles (RBCEV) Carmine to receive upfront, research funding, up to $900M milestones along with royalties on sales of therapies. Following the completion of […]Read More
